BAUSCH Health

News Releases

Register for email alerts.

All Categories

Archive

Date 12/20/13

Title

Valeant Pharmaceuticals To Present At Industry Conferences

Download PDF

Date 12/16/13

Title

Valeant Pharmaceuticals Agrees to Acquire Solta Medical for $2.92 Per Share in Cash

Download PDF

Date 12/13/13

Title

Valeant Pharmaceuticals To Hold Conference Call To Announce 2014 Financial Guidance

Download PDF

Date 12/02/13

Title

Valeant Pharmaceuticals Announces Redemption Of The Remaining $465.5 Million Aggrerate Principal Amount Of Its Outstanding 6.50% Senior Notes Due 2016

Download PDF

Date 11/25/13

Title

Valeant Pharmaceuticals Announces New Management Appointment

Download PDF

Date 11/15/13

Title

Valeant Pharmaceuticals Announces Pricing Of Private Offering Of Senior Notes

Download PDF

Date 11/15/13

Title

Valeant Pharmaceuticals Announced Redemption Of $450 Million Aggregate Principal Amount Of Its Outstanding 6.50% Senior Notes Due 2016

Download PDF

Date 11/15/13

Title

Valeant Pharmaceuticals Announces U.S. Approval Of Luzu® Cream, 1%

Download PDF

Date 11/15/13

Title

Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes

Download PDF

Date 10/31/13

Title

Valeant Pharmaceuticals Reports 2013 Third Quarter Financial Results

Download PDF

Date 10/28/13

Title

Valeant Pharmaceuticals Announces Settlement Agreement With Anacor

Download PDF

Date 10/18/13

Title

Valeant Pharmaceuticals Announces Award In Anacor Dispute

Download PDF

Date 10/08/13

Title

Valeant Pharmaceuticals To Announce 2013 Third Quarter Results On October 31, 2013

Download PDF

Date 10/03/13

Title

Valeant Pharmaceuticals Announces Approval Of Jublia® For The Treatment Of Onychomycosis In Canada

Download PDF

Date 10/03/13

Title

Valeant Pharmaceuticals' Bausch + Lomb Receives U.S. FDA Clearance For Novel Monthly Disposable Contact Lens

Download PDF

Date 10/02/13

Title

Valeant Pharmaceuticals Announces Partnership With National Coalition Against Domestic Violence

Download PDF

Date 08/09/13

Title

Valeant Pharmaceuticals Announces Continuance

Download PDF

Date 08/07/13

Title

Valeant Pharmaceuticals Reports 2013 Second Quarter Financial Results

Download PDF

Date 08/06/13

Title

Valeant Pharmaceuticals International, Inc. Completes Acquisition Of Bausch + Lomb

Download PDF

Date 07/15/13

Title

Valeant Pharmaceuticals To Announce 2013 Second Quarter Results On August 7, 2013

Download PDF

Date 07/02/13

Title

Medicis Announces Five-Year Aesthetic Collaboration with Mentor

Download PDF

Date 06/27/13

Title

Valeant Pharmaceuticals Announces Pricing Of Private Offering Of Senior Notes

Download PDF

Date 06/24/13

Title

Valeant Pharmaceuticals Announces Closing of Public Offering of Common Shares

Download PDF

Date 06/20/13

Title

Valeant Pharmaceuticals Announces Exercise Of Over-Allotment Option

Download PDF

Date 06/18/13

Title

Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes

Download PDF

Date 06/18/13

Title

Valeant Pharmaceuticals Prices Public Offering Of Common Shares

Download PDF

Date 06/17/13

Title

Valeant Pharmaceuticals Announces Public Offering Of Common Shares

Download PDF

Date 06/07/13

Title

Valeant Pharmaceuticals Announces Filing Of Preliminary Base Shelf Prospectus

Download PDF

Date 05/28/13

Title

Valeant Pharmaceuticals Announces Receipt Of U.S. FDA Complete Response Letter For Efinaconazole

Download PDF

Date 05/27/13

Title

Valeant Pharmaceuticals International, Inc. To Acquire Bausch + Lomb For $8.7 Billion

Download PDF

Date 05/21/13

Title

Valeant Pharmaceuticals Announces 2013 Annual Meeting Results

Download PDF

Date 05/20/13

Title

Valeant Pharmaceuticals To Present At 34th Annual Goldman Sachs Global Healthcare Conference

Download PDF

Date 05/15/13

Title

Valeant Pharmaceuticals Announces Resignation of Dr. Laurence Paul from Valeant's Board of Directors

Download PDF

Date 05/13/13

Title

Valeant Pharmaceuticals To Webcast 2013 Annual Meeting Of Shareholders

Download PDF

Date 05/10/13

Title

Valeant Pharmaceuticals International, Inc. Announces Additional Information Regarding Continuance Proposal

Download PDF

Date 05/02/13

Title

Valeant Pharmaceuticals Provides Efinconazole Update

Download PDF

Date 05/02/13

Title

Valeant Pharmaceuticals Reports 2013 First Quarter Financial Results

Download PDF

Date 05/01/13

Title

Actavis Acquires Worldwide Rights for Valeant's Metronidazole 1.3% Vaginal Gel

Download PDF

Date 04/25/13

Title

Valeant Pharmaceuticals International, Inc. Completes Tender Offer for Obagi Medical Products, Inc.

Download PDF

Date 04/24/13

Title

Valeant Pharmaceuticals International, Inc. Announces Receipt of Approval From the Antimonopoly Committee of Ukraine for its Previously Announced Acquisition of Obagi Medical Products, Inc.

Download PDF

Date 04/23/13

Title

Valeant Pharmaceuticals Announces Extension of the Expiration Date for Its Previously Announced Tender Offer for All Outstanding Shares of Common Stock of Obagi Medical Products, Inc.

Download PDF

Date 04/22/13

Title

Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance In The United States For Its Previously Announced Acquisition Of Obagi Medical Products, Inc.

Download PDF

Date 04/16/13

Title

Valeant Pharmaceuticals To Announce 2013 First Quarter Results On May 2, 2013

Download PDF

Date 04/10/13

Title

Actavis Reaches Agreements with Valeant to Launch Generic Versions of Ziana® and Zyclara®

Download PDF

Date 04/05/13

Title

Actavis and Valeant Announce Actavis as Exclusive Authorized Generic Marketer of Zovirax® Ointment; Co-Promotion Agreements on Zovirax® Cream and Cordran® Tape

Download PDF

Date 04/04/13

Title

Valeant Pharmaceuticals Provides Update to Recent Event

Download PDF

Date 04/03/13

Title

Valeant Pharmaceuticals And Obagi Medical Products Agree On An Increased Offer Price Of $24.00 Per Share In Cash

Download PDF

Date 03/29/13

Title

Valeant Pharmaceuticals Announces Private Exchange Offer

Download PDF

Date 03/20/13

Title

Valeant Pharmaceuticals International, Inc. Agrees to Acquire Obagi Medical Products, Inc. for $19.75 Per Share in Cash

Download PDF

Date 02/28/13

Title

Valeant Pharmaceuticals Reports 2012 Fourth Quarter Financial Results

Download PDF

Date 02/21/13

Title

Valeant Pharmaceuticals Acquires U.S. Rights to Targretin® from Eisai Inc.

Download PDF

Date 02/01/13

Title

Valeant Completes Acquisition Of Natur Produkt In Russia

Download PDF

Date 01/31/13

Title

Valeant Pharmaceuticals To Announce 2012 Fourth Quarter Results On February 28, 2013

Download PDF

Date 01/03/13

Title

Valeant Pharmaceuticals Announces New Management Appointment

Download PDF

Date 01/02/13

Title

Valeant Pharmaceuticals To Present At 31st Annual J.P. Morgan Healthcare Conference

Download PDF

Investor Inquiries
ir@bauschhealth.com
877-281-6642
514-856-3855 (Canada)

Media inquiries
Corporate.communications@bauschhealth.com
848-264-0934

LEGAL NOTICE PRIVACY POLICY

EMAIL ALERTS EMAIL PAGE RSS FEED

Use of this site signifies your agreement to the Legal Notice and Privacy Policy.
©2026 Bausch Health Companies Inc. All rights reserved. MTB.0230.USA.18 V2.0

CALIFORNIA RESIDENTS: DO NOT SELL MY PERSONAL INFORMATION

Powered by SITECORE